B2BROKER
4.4.2024 16:08:35 CEST | Business Wire | Press release
The latest major upgrade to B2Core was just released by B2Broker, significantly enhancing the platform's back-office and CRM solutions. The V2.1 upgrade delivers on the highly anticipated savings feature, introduces a new trading platform and PSP integrations, and drastically improves the user experience on the platform. Let’s explore:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404452158/en/
B2Broker, a leading liquidity and technology provider, has just announced the release of a new version of B2Core, its sophisticated CRM and back-office solution. B2Core V2.1 integrates the TradeLocker trading platform inside its ecosystem, adds new PSPs and enhances the existing ones, and upgrades its UI. (Photo: Business Wire)
Polished UI & Peak Performance
Version 2.1 of B2Core brings a new user interface, major functionality improvements, and technical fixes.
- A Withdrawal summary provides comprehensive transfer information that features commissions, exchange rates and the net transaction amount.
- Account creation now enforces minimum deposit settings to maintain consistency in the back-office.
- On the Deposit, Withdraw, and Transfer pages, accounts in selectors are now categorised by type (e.g., Fiat, Coins, MT4, MT5) for easier navigation.
- Platform consistency is guaranteed by the Unified Date Format.
- The old and new UI settings can now be easily switched by users.
Integration with TradeLocker Trading Platform
B2Core introduces TradeLocker, an innovative trading platform seamlessly integrated into the trader's room. This addition enhances the company’s existing suite of integrated platforms, including MetaTrader 4, MetaTrader 5, cTrader and B2Trader, offering brokerages a complex set of trading solutions.
TradeLocker presents a comprehensive suite of powerful trading tools and instruments aiming to cater to a wide spectrum of clients, from novices to seasoned traders. The platform is equipped with versatile features designed to support a variety of trading strategies and preferences, facilitating a seamless and efficient trading experience for brokerage clients.
TradeLocker integrates with TradingView to offer a sophisticated charting capability, granting users access to an extensive array of customisable charts and indicators. The platform provides traders with modern tools to manage risks effectively.
Among its standout features are SL & TP Calculator, On-Chart Trading, One-click Trading, Trailing Stop Loss, and Social Mode, enabling traders to efficiently manage their trades engaging with the market. Users can easily develop or customise bots, signals, indicators, and strategies using the TradeLocker AI at TradeLocker Studio.
Payment Improvements and Integrations
Thanks to the V2.1 B2Core update, users now have more transaction options, and the scope of payment integrations has expanded.
Sqala supports deposits and withdrawals in Brazilian reals (BRL). It is renowned for its simplicity, competitive exchange rates, and a convenient dashboard that provides all the essential data. By including Sqala in its portfolio, B2Broker has increased the range of its solutions and fulfilled the needs of customers worldwide.
Transactions have been streamlined and fortified through several new improvements:
- Within the B2Core environment, BridgerPay provides a better deposit process through an automated data fill-in feature that streamlines transaction processing.
- Praxis configuration has been enhanced to improve transaction security. To comply with diverse regulatory standards, you can now enable clients from various countries to submit specific documents.
- The constructor payment adjustments allow clients to attach documents for deposits and withdrawals, ensuring maximum compliance and record accuracy.
The V2.1 upgrade has also brought back access to 1-2-Pay and WireCustom for deposits and withdrawals to expand the choices for transfers.
Engage Customers with Savings Feature
Last but not least, V2.1 adds a savings feature that lets users invest idle funds and get interest over specific periods. The savings programs currently support fixed savings, allowing users to receive fixed-interest rewards. Moreover, admins can access, modify, and initiate new savings programs with the presets page, effortlessly incorporating both business and client preferences.
The savings feature offers flexibility across the board, allowing users to set customised annual interest rates and adjust investment duration with 30-day intervals (30, 60, or 90 days). Brokers may also impose an early withdrawal penalty to maintain the viability of their savings plans.
The savings feature is highly customisable and configurable. The annual interest earnings option will motivate the clients to retain their funds within the broker’s ecosystem. Additionally, it enables brokers to increase fund retention and liquidity within B2Core, resulting in an advantageous situation for everybody involved.
Final Remarks
B2Core continues B2Broker’s mission to deliver quality across all products and services, ensuring maximum client satisfaction. The V2.1 update is another testament to raising industry standards!
The team is working on the complete transition of B2Core to the new interface. Additionally, B2Core intends to offer flexible interest rates for the savings plans. The team also works hard to add new integrations and expansions, allowing clients to enjoy a comprehensive CRM and back-office solutions suite!
Explore B2Core’s new features today and discover the benefits for your business.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404452158/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom